Autologous Bone Marrow Aspirate Treatment for Early-Stage Osteonecrosis

Description

Osteonecrosis of the femoral head (ONFH) is a debilitating musculoskeletal disease that is characterized by localized death of bone cells and associated cellular elements within the subchondral bone. If it progresses, it results in the collapse of the femoral head (ball part of the hip) giving rise to secondary arthritis. This condition is associated with marked pain and loss of function, often necessitating a joint replacement. Due to the relatively young age of onset of ONFH (often in 20s and 30s), there is great interest in utilizing joint-preserving procedures prior to the need for joint replacement. Joint-preserving procedures include core decompression (CD) with and without bone grafts or cells, vascularized and non-vascularized bone grafting, as well as osteotomies. Inconsistent results for each of these procedures have been reported and there are no Clinical Practice Guidelines or medical community consensus opinions regarding the treatment of early-stage ONFH. The hypothesis to be tested is "Participants who have early-stage ONFH undergoing CD augmented with autogenous bone marrow aspirate concentrate will have better clinical and radiological outcomes than CD alone." This multi-center randomized controlled trial for early-stage ONFH is prospective and controlled for participant stage (only early-stage pre-collapse individuals) and surgical technique. Participants will be evaluated as per routine surgical follow-up, and at 6 months (telemedicine), 1- and 2- years using radiographs, MRIs, and questionnaires. This project will also explore the scientific basis for success vs. failure in individuals who have osteonecrosis, and have different demographics and bone marrow aspirate cell profiles.

Conditions

Osteonecrosis of the Femoral Head, Avascular Necrosis of the Femoral Head

Study Overview

Study Details

Study overview

Osteonecrosis of the femoral head (ONFH) is a debilitating musculoskeletal disease that is characterized by localized death of bone cells and associated cellular elements within the subchondral bone. If it progresses, it results in the collapse of the femoral head (ball part of the hip) giving rise to secondary arthritis. This condition is associated with marked pain and loss of function, often necessitating a joint replacement. Due to the relatively young age of onset of ONFH (often in 20s and 30s), there is great interest in utilizing joint-preserving procedures prior to the need for joint replacement. Joint-preserving procedures include core decompression (CD) with and without bone grafts or cells, vascularized and non-vascularized bone grafting, as well as osteotomies. Inconsistent results for each of these procedures have been reported and there are no Clinical Practice Guidelines or medical community consensus opinions regarding the treatment of early-stage ONFH. The hypothesis to be tested is "Participants who have early-stage ONFH undergoing CD augmented with autogenous bone marrow aspirate concentrate will have better clinical and radiological outcomes than CD alone." This multi-center randomized controlled trial for early-stage ONFH is prospective and controlled for participant stage (only early-stage pre-collapse individuals) and surgical technique. Participants will be evaluated as per routine surgical follow-up, and at 6 months (telemedicine), 1- and 2- years using radiographs, MRIs, and questionnaires. This project will also explore the scientific basis for success vs. failure in individuals who have osteonecrosis, and have different demographics and bone marrow aspirate cell profiles.

Autologous Bone Marrow Aspirate Concentrate for the Treatment of Osteonecrosis of the Femoral Head

Autologous Bone Marrow Aspirate Treatment for Early-Stage Osteonecrosis

Condition
Osteonecrosis of the Femoral Head
Intervention / Treatment

-

Contacts and Locations

Los Angeles

University of Southern California, Los Angeles, California, United States, 90033

Stanford

Stanford University, Stanford, California, United States, 94063

Baltimore

Sinai Hospital of Baltimore, Baltimore, Maryland, United States, 21215

Baltimore

Johns Hopkins University, Baltimore, Maryland, United States, 21224

Boston

Brigham and Women's Hospital, Boston, Massachusetts, United States, 02115

Minneapolis

University of Minnesota, Minneapolis, Minnesota, United States, 55455

Rochester

Mayo Clinic, Rochester, Minnesota, United States, 55905

New York

NYU Langone Health Orthopedic Hospital, New York, New York, United States, 11016

Durham

Duke University, Durham, North Carolina, United States, 27560

Cleveland

Cleveland Clinic, Cleveland, Ohio, United States, 441195

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

    Ages Eligible for Study

    18 Years to 90 Years

    Sexes Eligible for Study

    ALL

    Accepts Healthy Volunteers

    No

    Collaborators and Investigators

    Johns Hopkins University,

    Lynne C Jones, PhD, PRINCIPAL_INVESTIGATOR, Johns Hopkins University

    Michael A Mont, MD, PRINCIPAL_INVESTIGATOR, Sinai Hospital of Baltimore / LifeBridge Health

    Stuart B Goodman, MD, PhD, PRINCIPAL_INVESTIGATOR, Stanford University

    Study Record Dates

    2029-07-31